Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Meningeal Carcinomatosis 1Glioma 1Glioblastoma 1

Interventions

Specimen Handling 219pembrolizumab 198Magnetic Resonance Spectroscopy 197Carboplatin 174Cisplatin 140Biopsy 133Nivolumab 131Paclitaxel 115Radiotherapy 111Cyclophosphamide 111Gemcitabine 104durvalumab 90Dexamethasone 90atezolizumab 77Radiation 72Rituximab 71Lenalidomide 69Pemetrexed 66Bevacizumab 66Doxorubicin 65Docetaxel 63Ipilimumab 59Etoposide 57olaparib 54Fluorouracil 52venetoclax 50Taxes 50Oxaliplatin 50Radiosurgery 49Prednisone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × azeliragon × 90 days × Clear all
NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

NCT05986851 2026-03-31

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡